CA2359180C - Method and medicament for inhibiting the expression of a given gene - Google Patents

Method and medicament for inhibiting the expression of a given gene Download PDF

Info

Publication number
CA2359180C
CA2359180C CA002359180A CA2359180A CA2359180C CA 2359180 C CA2359180 C CA 2359180C CA 002359180 A CA002359180 A CA 002359180A CA 2359180 A CA2359180 A CA 2359180A CA 2359180 C CA2359180 C CA 2359180C
Authority
CA
Canada
Prior art keywords
dsrna
chemical linkage
medicament
use according
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002359180A
Other languages
English (en)
French (fr)
Other versions
CA2359180A1 (en
Inventor
Roland Kreutzer
Stephan Limmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Alnylam Europe AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26051592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2359180(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alnylam Europe AG filed Critical Alnylam Europe AG
Publication of CA2359180A1 publication Critical patent/CA2359180A1/en
Application granted granted Critical
Publication of CA2359180C publication Critical patent/CA2359180C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002359180A 1999-01-30 2000-01-29 Method and medicament for inhibiting the expression of a given gene Expired - Lifetime CA2359180C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19903713.2 1999-01-30
DE19903713 1999-01-30
DE19956568.6 1999-11-24
DE19956568A DE19956568A1 (de) 1999-01-30 1999-11-24 Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
PCT/DE2000/000244 WO2000044895A1 (de) 1999-01-30 2000-01-29 Verfahren und medikament zur hemmung der expression eines vorgegebenen gens

Publications (2)

Publication Number Publication Date
CA2359180A1 CA2359180A1 (en) 2000-08-03
CA2359180C true CA2359180C (en) 2007-06-12

Family

ID=26051592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002359180A Expired - Lifetime CA2359180C (en) 1999-01-30 2000-01-29 Method and medicament for inhibiting the expression of a given gene

Country Status (13)

Country Link
US (17) US8119608B2 (https=)
EP (6) EP1214945B2 (https=)
JP (14) JP2003502012A (https=)
AT (3) ATE297463T1 (https=)
AU (2) AU778474B2 (https=)
CA (1) CA2359180C (https=)
CY (3) CY1108896T1 (https=)
DE (7) DE19956568A1 (https=)
DK (4) DK1798285T3 (https=)
ES (5) ES2243608T5 (https=)
PT (4) PT1550719E (https=)
WO (1) WO2000044895A1 (https=)
ZA (1) ZA200105909B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
CN101525388B (zh) * 2009-02-20 2012-02-01 中国人民解放军第四军医大学 特异性双链rna结合蛋白嵌合体及其在病毒感染性疾病中的应用
US8329463B2 (en) 2000-12-01 2012-12-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8524681B2 (en) 2007-09-19 2013-09-03 Applied Biosystems, Llc siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof

Families Citing this family (666)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US20030216335A1 (en) * 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
US20070021979A1 (en) * 1999-04-16 2007-01-25 Cosentino Daniel L Multiuser wellness parameter monitoring system
WO2000063364A2 (en) * 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7531718B2 (en) 1999-08-26 2009-05-12 Monsanto Technology, L.L.C. Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7067722B2 (en) 1999-08-26 2006-06-27 Monsanto Technology Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
CN1378602A (zh) 1999-08-26 2002-11-06 卡尔根尼有限公司 含修饰的多不饱和脂肪酸的植物
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10160151A1 (de) * 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
WO2005019453A2 (en) * 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
BRPI0117338B1 (pt) * 2000-03-30 2016-06-21 Massachusetts Inst Technology método para produzir células animais nocauteadas in vitro e método para produzir uma célula nocauteada
US20080032942A1 (en) 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
CA2427347C (en) * 2000-10-31 2011-01-18 Commonwealth Scientific And Industrial Research Organisation Method and means for producing barley yellow dwarf virus resistant cereal plants
US20020173478A1 (en) * 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
DE10100587C1 (de) * 2001-01-09 2002-11-21 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
DE10100588A1 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
WO2003035869A1 (de) * 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
GB0104948D0 (en) * 2001-02-28 2001-04-18 Novartis Res Foundation Novel methods
WO2005078097A2 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
US20050158735A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003070888A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
WO2003070969A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
EP1572067A4 (en) * 2001-05-18 2009-05-13 Sirna Therapeutics Inc CONJUGATES AND COMPOSITIONS FOR CELLULAR RELEASE
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
WO2005014811A2 (en) * 2003-08-08 2005-02-17 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050159381A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
WO2004097020A2 (en) * 2003-04-25 2004-11-11 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase gene expression
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
WO2003070887A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US8008472B2 (en) 2001-05-29 2011-08-30 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
EP2345720A3 (en) 2001-07-12 2012-01-25 University of Massachusetts In vivo production of small interfering RNAs that mediate gene silencing
US8022272B2 (en) 2001-07-13 2011-09-20 Sungene Gmbh & Co. Kgaa Expression cassettes for transgenic expression of nucleic acids
CA2452653A1 (en) * 2001-07-17 2003-01-30 Anne Josephine Milner Silencing of gene expression by sirna
ES2386775T3 (es) 2001-07-23 2012-08-30 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US7456335B2 (en) * 2001-09-03 2008-11-25 Basf Plant Science Gmbh Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
CN1608133A (zh) * 2001-10-26 2005-04-20 里伯药品公司 双链核糖核酸用于治疗正(+)链rna病毒感染的用途
DE10230996A1 (de) * 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Behandlung eines Pankreaskarzinoms
WO2003035083A1 (de) * 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2213737B1 (en) * 2002-02-01 2012-11-07 Life Technologies Corporation Double-stranded oligonucleotides
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US7700760B2 (en) 2002-02-20 2010-04-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US7893248B2 (en) 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US7928220B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
EP1474433A4 (en) * 2002-02-20 2005-02-23 Sirna Therapeutics Inc TARGET LOCALIZATION TARGETED BY RNA INTERFERENCE AND TARGET VALIDATION WITH SHORT INTERFERING NUCLEIC ACID (siNA)
US7691999B2 (en) 2002-02-20 2010-04-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7667030B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
EP1710307A3 (en) * 2002-02-20 2007-06-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US7928219B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
US7897757B2 (en) 2002-02-20 2011-03-01 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US8258288B2 (en) 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
EP1476459A4 (en) * 2002-02-20 2005-05-25 Sirna Therapeutics Inc INHIBITION OF RNA INTERFERENCE-INDUCED CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20090253773A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US7910724B2 (en) 2002-02-20 2011-03-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
EP1478730A4 (en) * 2002-02-20 2006-01-25 Sirna Therapeutics Inc INTERFERENCE RNA-INDUCED INHIBITION OF THE GENE EXPRESSION OF SUPERFAMILY TFN AND TFN RECEPTOR SUPERFAMILY USING SHORT INTERFERENCE NUCLEIC ACID (SINA)
US20090247613A1 (en) * 2002-02-20 2009-10-01 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8013143B2 (en) 2002-02-20 2011-09-06 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
GB2397062B (en) * 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
JP2005517423A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＴＧＦ−ベータおよびＴＧＦ−ベータレセプター遺伝子の発現のＲＮＡ干渉媒介性阻害
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
AU2003216255A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
EP1741781A3 (en) * 2002-02-20 2007-06-06 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7662952B2 (en) 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
US8067575B2 (en) 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US8232383B2 (en) * 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003219818A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Incorporated RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20090253774A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7678897B2 (en) 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20090137510A1 (en) * 2002-02-20 2009-05-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003210895A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Inc. Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina)
US7166771B2 (en) 2002-06-21 2007-01-23 Monsanto Technology Llc Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
AR039113A1 (es) 2002-03-21 2005-02-09 Monsanto Technology Llc Construcciones de acidos nucleicos y metodos para producir composiciones de aceites de semillas alteradas
US7566813B2 (en) 2002-03-21 2009-07-28 Monsanto Technology, L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
AU2003228667A1 (en) * 2002-04-22 2003-12-19 Sirna Therapeutics Inc. Nucleic acid mediated disruption of hiv fusogenic peptide interactions
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
US7399586B2 (en) 2002-05-23 2008-07-15 Ceptyr, Inc. Modulation of biological signal transduction by RNA interference
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
AU2003276666A1 (en) * 2002-06-12 2003-12-31 Ambion, Inc. Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US7655790B2 (en) 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US7399851B2 (en) 2002-07-25 2008-07-15 Dana Farber Cancer Institute, Inc. Composition and method for imaging cells
ATE405658T1 (de) 2002-07-26 2008-09-15 Basf Plant Science Gmbh Neue selektionsverfahren
US20040241854A1 (en) * 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
ES2389024T3 (es) * 2002-08-05 2012-10-22 Silence Therapeutics Aktiengesellschaft Moléculas de RNA interferentes de extremos romos
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
AU2003260370B2 (en) 2002-08-05 2008-05-22 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
WO2004018687A2 (en) 2002-08-07 2004-03-04 Basf Plant Science Gmbh Nucleic acid sequences encoding proteins associated with abiotic stress response
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
AU2003256615A1 (en) 2002-08-12 2004-02-25 New England Biolabs, Inc. Methods and compositions relating to gene silencing
EP1393742A1 (en) 2002-08-14 2004-03-03 atugen AG Use of protein kinase N beta
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
US20060030534A1 (en) 2002-09-04 2006-02-09 Gabriele Dorn Treatment of neurological disorders by dsrna administration
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040053289A1 (en) * 2002-09-09 2004-03-18 The Regents Of The University Of California Short interfering nucleic acid hybrids and methods thereof
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US7122361B2 (en) 2002-10-10 2006-10-17 Wyeth Compositions employing a novel human kinase
EP2072619A1 (en) 2002-10-18 2009-06-24 Silence Therapeutics Aktiengesellschaft Factor involved in metastasis and uses thereof
CA2503491A1 (en) 2002-10-24 2004-05-06 Wyeth Calcineurin-like human phosphoesterase
NZ540779A (en) 2002-11-01 2008-05-30 Univ Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003287505A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
JP2006505280A (ja) * 2002-11-07 2006-02-16 チャン・ルン−ジ 改変樹状細胞
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
JP4526228B2 (ja) * 2002-11-22 2010-08-18 隆 森田 ＲＮＡｉによる新規治療法および治療剤
US7297525B2 (en) 2002-11-27 2007-11-20 Wyeth Composition employing a novel human kinase
DE602004028587D1 (de) 2003-01-16 2010-09-23 Univ Pennsylvania ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1
EP1592708A2 (en) 2003-02-14 2005-11-09 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
WO2004080406A2 (en) 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
CA2519860C (en) * 2003-03-21 2018-01-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
CA2521464C (en) 2003-04-09 2013-02-05 Alnylam Pharmaceuticals, Inc. Irna conjugates
US20090298914A1 (en) * 2003-04-15 2009-12-03 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (SARS) Virus Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20070270360A1 (en) * 2003-04-15 2007-11-22 Sirna Therapeutics, Inc. Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
JP4991288B2 (ja) 2003-04-17 2012-08-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
CA2522730A1 (en) 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2
EP1622572B1 (en) 2003-04-30 2017-12-20 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
BRPI0410886A (pt) 2003-06-03 2006-07-04 Isis Pharmaceuticals Inc composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
US7595306B2 (en) 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
AU2004263830B2 (en) 2003-06-13 2008-12-18 Alnylam Pharmaceuticals, Inc. Double-stranded ribonucleic acid with increased effectiveness in an organism
WO2005001062A2 (en) * 2003-06-25 2005-01-06 Gencia Corporation Modified vectors for organelle transfection
CA2528963A1 (en) * 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
WO2005007859A2 (en) * 2003-07-11 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2004262656A1 (en) 2003-08-01 2005-02-17 Basf Plant Science Gmbh Process for the production of fine chemicals in plants
CN1845993B (zh) 2003-08-28 2010-06-23 诺瓦提斯公司 具有平端和3＇修饰的干扰rna双链体
US20070202505A1 (en) * 2003-09-08 2007-08-30 Alex Chenchik Methods for gene function analysis
WO2005045037A2 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
ATE503014T1 (de) * 2003-11-04 2011-04-15 Geron Corp Rna-amidate und thioamidateur rnai
JP5654722B2 (ja) * 2003-11-26 2015-01-14 ユニバーシティ オブ マサチューセッツ 短鎖ｒｎａ機能の配列特異的阻害法
CN102321584B (zh) 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
JP4755113B2 (ja) 2004-01-30 2011-08-24 クアーク・ファーマスーティカルス、インコーポレイテッド 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法
WO2005073378A1 (en) * 2004-01-30 2005-08-11 Santaris Pharma A/S MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
US20090280567A1 (en) * 2004-02-06 2009-11-12 Dharmacon, Inc. Stabilized sirnas as transfection controls and silencing reagents
EP2123759B1 (en) * 2004-02-06 2014-01-15 Thermo Fisher Scientific Biosciences Inc. Stabilized RNAS as transfection controls and silencing reagents
AU2005213464A1 (en) 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
US20060019914A1 (en) 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
ATE514434T1 (de) 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
AU2005222902B2 (en) 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
ES2671522T3 (es) 2004-04-02 2018-06-06 The Regents Of The University Of California Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5
AU2005238034A1 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Of New York Inhibition of hairless protein mRNA
DE102004025881A1 (de) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP2290071B1 (en) 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
US20060003410A1 (en) * 2004-06-10 2006-01-05 Lee-Ming Chuang Prostaglandin reductase
JP4852539B2 (ja) 2004-06-22 2012-01-11 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 腫瘍細胞増殖をＦＯＸＭ１ｓｉＲＮＡによって阻害する方法
WO2007087815A2 (en) 2004-12-17 2007-08-09 Metanomics Gmbh Process for the control of production of fine chemicals
AU2005321630A1 (en) 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
WO2006002538A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
US7968762B2 (en) 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
US20100132058A1 (en) 2004-07-23 2010-05-27 Diatchenko Luda B Methods and materials for determining pain sensitivity and predicting and treating related disorders
CN101001951B (zh) 2004-08-02 2011-06-15 巴斯福植物科学有限公司 分离转录终止序列的方法
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
JP4468989B2 (ja) 2004-08-16 2010-05-26 クアーク・ファーマスーティカルス、インコーポレイテッド Ｒｔｐ８０１阻害剤の治療への使用
CA2577036A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
JP2008512500A (ja) 2004-09-10 2008-04-24 ソマジェニックス インコーポレーティッド ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法
CA2579927A1 (en) 2004-09-24 2006-03-30 Basf Plant Science Gmbh Plant cells and plants with increased tolerance to environmental stress
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
EP2163632A1 (en) 2004-10-05 2010-03-17 SunGene GmbH Constitutive expression cassettes for regulation of plant expression
JP2008515458A (ja) 2004-10-13 2008-05-15 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド 線虫抵抗性の遺伝子組換え植物
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP1655364A3 (en) 2004-11-05 2006-08-02 BASF Plant Science GmbH Expression cassettes for seed-preferential expression in plants
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US7935811B2 (en) * 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
EP1662000B1 (en) 2004-11-25 2011-03-30 SunGene GmbH Expression cassettes for guard cell-preferential expression in plants
EP1666599A3 (en) 2004-12-04 2006-07-12 SunGene GmbH Expression cassettes for mesophyll- and/or epidermis-preferential expression in plants
EP1669455B1 (en) 2004-12-08 2009-10-28 SunGene GmbH Expression cassettes for vascular tissue-preferential expression in plants
EP1669456A3 (en) 2004-12-11 2006-07-12 SunGene GmbH Expression cassettes for meristem-preferential expression in plants
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
CN101287497B (zh) 2004-12-27 2013-03-06 赛伦斯治疗公司 涂层脂质复合体和它们的用途
WO2006074108A2 (en) * 2004-12-30 2006-07-13 Hauser Todd M Compositions and methods for modulating gene expression using self-protected oligonucleotides
WO2006072887A1 (en) 2005-01-05 2006-07-13 Eyegate Pharma Sa Ocular iontophoresis device for delivering sirna and aptamers
EP1841793B1 (en) 2005-01-07 2010-03-31 Diadexus, Inc. Ovr110 antibody compositions and methods of use
TW200639252A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
EP2147977A1 (en) 2005-02-09 2010-01-27 BASF Plant Science GmbH Expression cassettes for regulation of expression in monocotyledonous plants
CN101128591B (zh) 2005-02-26 2013-02-13 巴斯福植物科学有限公司 用于植物中种子偏好性表达的表达盒
JPWO2006093083A1 (ja) * 2005-03-03 2008-08-07 和光純薬工業株式会社 架橋剤、架橋法、遺伝子発現調節法及び遺伝子機能調査法
CN101137752B (zh) 2005-03-08 2013-04-03 巴斯福植物科学有限公司 增强表达的内含子序列
KR20080018858A (ko) 2005-03-11 2008-02-28 알콘, 인코퍼레이티드 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해
US20060223777A1 (en) * 2005-03-29 2006-10-05 Dharmacon, Inc. Highly functional short hairpin RNA
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
WO2006112401A1 (ja) * 2005-04-18 2006-10-26 National University Corporation Hamamatsu University School Of Medicine 癌治療用組成物
US20090203055A1 (en) * 2005-04-18 2009-08-13 Massachusetts Institute Of Technology Compositions and methods for RNA interference with sialidase expression and uses thereof
AU2006245701B2 (en) 2005-05-10 2011-04-28 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
JP2008540571A (ja) * 2005-05-12 2008-11-20 ウィスコンシン・アルムニ・リサーチ・ファウンデーション Ｐｉｎ１の遮断は活性化した免疫細胞によるサイトカイン産生を防ぐ
FR2885808B1 (fr) 2005-05-19 2007-07-06 Oreal Vectorisation de dsrna par des particules cationiques et utilisation topique.
BRPI0612671A2 (pt) 2005-06-23 2010-11-30 Basf Plant Science Gmbh métodos melhorados para a produção de plantas férteis zea mays (milho) estavelmente transformadas
US8703769B2 (en) 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
EP1764107A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
EP2980220A1 (en) 2005-09-20 2016-02-03 BASF Plant Science GmbH Improved methods controlling gene expression
US8093369B2 (en) 2005-10-11 2012-01-10 Ben Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of VDAC1 and uses thereof
WO2007051045A2 (en) 2005-10-28 2007-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
EP1942948A4 (en) 2005-11-04 2010-03-03 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE
CA2628505A1 (en) 2005-11-08 2007-05-18 Basf Plant Science Gmbh Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
CA2631621C (en) 2005-11-29 2019-08-06 Cambridge Enterprise Limited Markers for breast cancer including rs2981582
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
PL1966240T6 (pl) 2005-12-30 2012-05-31 Evonik Roehm Gmbh Peptydy laktoferyny użyteczne jako peptydy penetrujące komórkę
CA2636070A1 (en) 2006-01-06 2007-08-02 North Carolina State University Cyst nematode resistant transgenic plants
EP1979484B1 (en) 2006-01-12 2014-03-19 BASF Plant Science GmbH Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
DK1984382T3 (da) * 2006-01-27 2012-09-03 Santaris Pharma As LNA modificerede fosforthiolerede oligonukleotider
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
CN101421406B (zh) 2006-02-13 2016-08-31 孟山都技术有限公司 用于产生改变的种子油组成的核酸构建体和方法
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
WO2007107162A2 (en) 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
US8968702B2 (en) 2006-03-30 2015-03-03 Duke University Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
US7718629B2 (en) 2006-03-31 2010-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 gene
EP2090662A3 (en) 2006-04-05 2012-10-31 Metanomics GmbH Process for the production of a fine chemical
CN101622273A (zh) 2006-04-13 2010-01-06 诺瓦提斯疫苗和诊断公司 治疗、诊断或检测与liv-1过量表达相关的癌症的方法
WO2007127919A2 (en) 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
ES2874149T3 (es) 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
EP2392583A1 (en) 2006-05-19 2011-12-07 Alnylam Europe AG. RNAi modulation of Aha and therapeutic uses thereof
EP2584051B1 (en) 2006-05-22 2014-07-16 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expressions of IKK-B gene
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
CN101511181B (zh) 2006-07-11 2013-08-21 新泽西医科和牙科大学 蛋白、编码该蛋白的核酸和相关的应用方法
AU2007276388A1 (en) 2006-07-21 2008-01-24 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
EP2074209A2 (en) 2006-07-28 2009-07-01 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
AU2007297388A1 (en) 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. RNAi modulation of scap and therapeutic uses thereof
AU2007299629C1 (en) 2006-09-21 2012-05-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the HAMP gene
WO2008036841A2 (en) * 2006-09-22 2008-03-27 Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
EP2078079B1 (en) 2006-11-01 2011-05-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
US8444971B2 (en) 2006-11-27 2013-05-21 Diadexus, Inc. OVR110 antibody compositions and methods of use
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
US20100129358A1 (en) 2006-12-22 2010-05-27 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
US8592652B2 (en) 2007-01-15 2013-11-26 Basf Plant Science Gmbh Use of subtilisin-like RNR9 polynucleotide for achieving pathogen resistance in plants
US8455188B2 (en) 2007-01-26 2013-06-04 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
CA2675926A1 (en) 2007-02-16 2008-08-21 Basf Plant Science Gmbh Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
US7872119B2 (en) 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
US8846005B2 (en) 2007-03-14 2014-09-30 Novartis Ag APCDD1 inhibitors for treating, diagnosing or detecting cancer
PL2129680T3 (pl) 2007-03-21 2015-10-30 Brookhaven Science Ass Llc Łączone kompozycje cząsteczek antysensownych o strukturze spinki do włosów oraz sposoby modulacji ekspresji
US7812002B2 (en) 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
AU2008232891B2 (en) 2007-03-29 2012-01-12 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the Ebola
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
CN101686939B (zh) 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
WO2009014565A2 (en) 2007-04-26 2009-01-29 Ludwig Institute For Cancer Research, Ltd. Methods for diagnosing and treating astrocytomas
US20100291042A1 (en) 2007-05-03 2010-11-18 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
BRPI0811170B8 (pt) 2007-05-22 2021-05-25 Arcturus Therapeutics Inc oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
AU2008252998A1 (en) 2007-05-22 2008-11-27 Basf Plant Science Gmbh Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production-KO
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
WO2009001359A2 (en) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
ES2428009T3 (es) 2007-07-05 2013-11-05 Novartis Ag ARNds para tratar infecciones virales
US9689031B2 (en) 2007-07-14 2017-06-27 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
US8012474B2 (en) 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
EP2192916A4 (en) * 2007-08-23 2012-04-04 Univ Leland Stanford Junior MODULATION OF SYNAPTOGENESIS
WO2009033027A2 (en) 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20100280097A1 (en) * 2007-09-18 2010-11-04 Intradigm Corporation Compositions comprising hif-1 alpha sirna and methods of use thereof
CA2704737A1 (en) * 2007-09-18 2009-09-03 Intradigm Corporation Compositions comprising k-ras sirna and methods of use
AU2008306455C1 (en) 2007-10-03 2014-04-17 Quark Pharmaceuticals, Inc. Novel siRNA structures
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
US8097712B2 (en) * 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
EP2848688A1 (en) 2007-12-10 2015-03-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor VII gene
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
CN101952444A (zh) * 2007-12-21 2011-01-19 巴斯夫植物科学有限公司 产量提高的植物(ko nue)
WO2009090639A2 (en) * 2008-01-15 2009-07-23 Quark Pharmaceuticals, Inc. Sirna compounds and methods of use thereof
US10131904B2 (en) 2008-02-11 2018-11-20 Rxi Pharmaceuticals Corporation Modified RNAi polynucleotides and uses thereof
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
SG188121A1 (en) 2008-03-05 2013-03-28 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of eg5 and vegf genes
WO2009114726A1 (en) * 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising notch1 sirna and methods of use thereof
CN102037123A (zh) 2008-04-04 2011-04-27 卡兰多制药股份有限公司 Epas1抑制剂的组合物和用途
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US8278287B2 (en) 2008-04-15 2012-10-02 Quark Pharmaceuticals Inc. siRNA compounds for inhibiting NRF2
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
JP5524189B2 (ja) 2008-06-06 2014-06-18 クォーク ファーマシューティカルズ インコーポレーティッド 耳障害治療のための組成物および方法
TWI455944B (zh) 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids
WO2011028218A1 (en) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Process for triphosphate oligonucleotide synthesis
EP3208337A1 (en) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Compositions for combined inhibition of mutant egfr and il-6 expression
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
EP2342616A2 (en) 2008-09-23 2011-07-13 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
CA2739170A1 (en) 2008-09-25 2010-04-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
AR075549A1 (es) 2008-09-29 2011-04-20 Monsanto Technology Llc Evento transgenico de soja mon87705 y metodos para detectar el mismo
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8283460B2 (en) * 2008-10-15 2012-10-09 Somagenics, Inc. Short hairpin RNAs for inhibition of gene expression
EA036772B1 (ru) 2008-10-20 2020-12-18 Элнилэм Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии транстиретина
EP2350264A4 (en) 2008-11-06 2012-08-29 Univ Johns Hopkins TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT
HUE037082T2 (hu) 2008-11-10 2018-08-28 Arbutus Biopharma Corp Új lipidek és készítmények terápiás hatóanyagok szállítására
EP2687609B1 (en) 2008-11-10 2017-01-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for treating solid tumor
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
SG171879A1 (en) 2008-12-03 2011-07-28 Marina Biotech Inc Usirna complexes
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
EP2373382B1 (en) 2008-12-10 2017-02-15 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
EP2370175A2 (en) 2008-12-16 2011-10-05 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
WO2010080452A2 (en) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS AND METHODS OF USE THEREOF
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
KR101805199B1 (ko) * 2009-02-12 2017-12-05 큐알엔에이, 인크. 신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ) 관련된 질환의 치료
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
EP2669290A1 (en) 2009-03-02 2013-12-04 Alnylam Pharmaceuticals Inc. Nucleic Acid Chemical Modifications
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2408917A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2010229847A1 (en) 2009-03-27 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
US8283332B2 (en) 2009-04-17 2012-10-09 University Of Louisville Research Foundation, Inc. PFKFB4 inhibitors and methods of using the same
UA109110C2 (ru) 2009-04-22 2015-07-27 Басф Плант Саєнс Компані Гмбх Полинуклеотид, который обеспечивает возможность специфической экспрессии в целых семенах однодольного растения
EP2427180B1 (en) 2009-05-05 2016-04-13 Beeologics Inc. Prevention and treatment of nosema disease in bees
ES2804764T3 (es) 2009-06-01 2021-02-09 Halo Bio Rnai Therapeutics Inc Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
EP2258858A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Transgenic LSD1 animal model for cancer
MX342785B (es) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
EP2266550A1 (en) 2009-06-15 2010-12-29 Institut Curie Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
AU2010270309A1 (en) 2009-07-10 2012-02-02 Basf Plant Science Company Gmbh Expression cassettes for endosperm-specific expression in plants
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
SI2453923T1 (sl) 2009-07-14 2016-04-29 Mayo Foundation For Medical Education And Research S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere
SMT201700293T1 (it) 2009-07-20 2017-07-18 Bristol Myers Squibb Co Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative
CA2767409C (en) 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
US20110039789A1 (en) * 2009-08-14 2011-02-17 Institut Curie Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer
US9029338B2 (en) 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
US20150025122A1 (en) 2009-10-12 2015-01-22 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
BR112012012254B1 (pt) 2009-11-23 2020-11-24 Aquabounty Technologies, Inc Construto de expressao isolado, e, metodos para produzir um peixe femea de finalizaqao de linhagem, para propagar peixes transgenicos com construto de esterilidade materna, e para gerar uma geraqao esteril de peixes
DK2504435T3 (da) 2009-11-26 2019-12-09 Quark Pharmaceuticals Inc Sirna-forbindelser omfattende terminale substitutioner
CN102782141A (zh) 2009-12-03 2012-11-14 巴斯夫植物科学有限公司 用于在植物中胚-特异性表达的表达盒
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
CA2785996C (en) 2009-12-07 2021-04-13 The Johns Hopkins University Sr-bi as a predictor of human female infertility and responsiveness to treatment
EP2510098B1 (en) 2009-12-09 2015-02-11 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
KR101718534B1 (ko) 2009-12-09 2017-03-22 닛토덴코 가부시키가이샤 Ｈｓｐ４７ 발현의 조절
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
WO2011072243A1 (en) 2009-12-10 2011-06-16 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
CA2784568A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Lipid particles for delivery of nucleic acids
EP3000885B1 (en) 2009-12-18 2018-07-25 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
US8673565B2 (en) 2010-01-26 2014-03-18 National Jewish Health Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011094580A2 (en) 2010-01-28 2011-08-04 Alnylam Pharmaceuticals, Inc. Chelated copper for use in the preparation of conjugated oligonucleotides
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
US8945927B2 (en) 2010-03-29 2015-02-03 Universite De Strasbourg Polymers for delivering molecules of interest
EP3329924B1 (en) 2010-03-29 2021-05-05 Alnylam Pharmaceuticals, Inc. Dsrna therapy for transthyretin (ttr) related ocular amyloidosis
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
CA2792561C (en) 2010-04-06 2021-10-26 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
CA3098080A1 (en) 2010-04-23 2011-10-27 Arrowhead Research Corporation Organic compositions to treat beta-enac-related diseases
KR101223660B1 (ko) 2010-05-20 2013-01-17 광주과학기술원 ＨＩＦ－２α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
AU2011255203B2 (en) 2010-05-21 2016-01-21 Peptimed, Inc. Reagents and methods for treating cancer
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US20130149320A1 (en) 2010-05-31 2013-06-13 Centre National De La Recherche Scientifique Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
CA2801066C (en) 2010-06-02 2021-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
WO2011163121A1 (en) 2010-06-21 2011-12-29 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
US9168297B2 (en) 2010-06-23 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (NRG-1)
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
CA2816584A1 (en) 2010-11-01 2012-05-10 Peptimed, Inc. Compositions of a peptide-based system for cell-specific targeting
ES2746554T3 (es) 2010-11-02 2020-03-06 Univ Columbia Métodos para tratar los trastornos de pérdida de cabello
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2455456A1 (en) 2010-11-22 2012-05-23 Institut Curie Use of kinesin inhibitors in HIV infection treatment and a method for screening them
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
AU2011338682B2 (en) 2010-12-06 2017-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising threose modifications
WO2012102793A2 (en) 2010-12-10 2012-08-02 Zirus, Inc. Mammalian genes involved in toxicity and infection
WO2012088420A1 (en) 2010-12-22 2012-06-28 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and usese thereof
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
CN103492572A (zh) 2011-03-03 2014-01-01 夸克医药公司 用于治疗肺疾病和损伤的组合物和方法
CN103562387A (zh) 2011-03-03 2014-02-05 夸克医药公司 Toll样受体途径的寡核苷酸调剂
WO2012119764A1 (en) 2011-03-08 2012-09-13 Società Bulloneria Europea S.B.E. Spa A high load flanged fastener to be installed by tensioning tools
SG193499A1 (en) 2011-03-15 2013-10-30 Univ Utah Res Found Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
KR101291668B1 (ko) 2011-04-21 2013-08-01 서울대학교산학협력단 미코박테리아―대장균용 셔틀 벡터 및 이의 용도
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
CN103649103A (zh) 2011-06-21 2014-03-19 阿尔尼拉姆医药品有限公司 用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
EP2723861A4 (en) 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
WO2012177949A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein c (proc) genes
EP3366312A1 (en) 2011-06-23 2018-08-29 Alnylam Pharmaceuticals, Inc. Serpina 1 sirnas: compositions of matter and methods of treatment
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
CN103930547A (zh) 2011-09-02 2014-07-16 诺华股份有限公司 用于治疗hsf1相关疾病的有机组合物
CA2857374A1 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Camkii, ip3r, calcineurin, p38 and mk2/3 inhibitors to treat metabolic disturbances of obesity
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US9352312B2 (en) 2011-09-23 2016-05-31 Alere Switzerland Gmbh System and apparatus for reactions
EP2760477B1 (en) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
CN103917556B (zh) 2011-10-14 2018-02-06 霍夫曼-拉罗奇有限公司 抗HtrA1抗体及使用方法
JP6294229B2 (ja) 2011-10-18 2018-03-14 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アミン陽イオン性脂質およびその使用
JP6118331B2 (ja) 2011-11-03 2017-04-19 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 神経保護のための方法および組成物
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
KR101371696B1 (ko) 2012-02-02 2014-03-07 세종대학교산학협력단 벼도열병 발병인자의 스크리닝 방법
CA2863964C (en) 2012-02-07 2021-10-26 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
EP3459565A1 (en) 2012-03-29 2019-03-27 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
EP3272868A1 (en) 2012-05-02 2018-01-24 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat kras-related diseases
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2849771A1 (en) 2012-05-16 2015-03-25 Silence Therapeutics GmbH Use of vegfr1 as a biomarker for pkn3 inhibitor administration
WO2013187556A1 (en) 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
EP2867368B1 (en) 2012-07-06 2022-01-12 Institut Gustave Roussy Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
WO2014018554A1 (en) 2012-07-23 2014-01-30 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
EP2700949A1 (en) 2012-08-24 2014-02-26 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Use of biliverdin reductase proteins as cancer marker
AU2013329372B2 (en) 2012-10-08 2018-07-12 St. Jude Children's Research Hospital Therapies based on control of regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
US10125369B2 (en) 2012-12-05 2018-11-13 Alnylam Pharmaceuticals, Inc. PCSK9 iRNA compositions and methods of use thereof
SG10201706960TA (en) 2013-02-28 2017-10-30 Arrowhead Res Corp Organic compositions to treat epas1-related diseases
WO2014135655A1 (en) 2013-03-06 2014-09-12 Institut Curie Compositions and methods for treating muscle-invasive bladder cancer
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
KR102127358B1 (ko) 2013-03-13 2020-06-29 지니위브 바이오사이언시스, 인코포레이티드 비-복제 형질도입 입자 및 형질도입 입자-기반 리포터 시스템
US9920377B2 (en) 2013-03-15 2018-03-20 Sutter West Bay Hospitals FALZ for use as a target for therapies to treat cancer
CA2907152A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
EP2978446B1 (en) 2013-03-27 2020-03-04 The General Hospital Corporation Anti-cd33 antibody for use in treating alzheimer's disease
JP6896420B2 (ja) 2013-07-03 2021-06-30 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 抗癌組成物
CN105518136A (zh) 2013-07-10 2016-04-20 巴斯夫欧洲公司 用于通过抑制CYP51基因表达来控制致植物病真菌和卵菌的RNAi
EP3030663B1 (en) 2013-07-19 2019-09-04 Monsanto Technology LLC Compositions and methods for controlling leptinotarsa
US9889200B2 (en) 2013-07-31 2018-02-13 Qbi Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
EP3027223A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
WO2015021443A1 (en) 2013-08-08 2015-02-12 Global Bio Therapeutics Usa, Inc. Clamp device for minimally invasive procedures and uses thereof
HK1225257B (en) 2013-08-08 2017-09-08 Global Bio Therapeutics, Inc. Injection device for minimally invasive surgical procedures
EP3052627B1 (en) 2013-10-04 2018-08-22 Novartis AG Novel formats for organic compounds for use in rna interference
WO2015051044A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
WO2015051135A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compositions to treat hepcidin-related diseases
EP3052107B1 (en) 2013-10-04 2018-05-02 Novartis AG Organic compounds to treat hepatitis b virus
JP6694811B2 (ja) 2013-10-04 2020-05-20 ノバルティス アーゲー ＲＮＡ干渉に使用するためのＲＮＡｉ剤用の３’末端キャップ
EP3055426B1 (en) 2013-10-09 2019-06-19 The United States of America as represented by The Secretary Department of Health and Human Services Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
KR20160068855A (ko) 2013-10-11 2016-06-15 제넨테크, 인크. Nsp4 억제제 및 사용 방법
US10004814B2 (en) 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
WO2015084897A2 (en) 2013-12-02 2015-06-11 Mirimmune, Llc Immunotherapy of cancer
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
US9274117B2 (en) 2013-12-21 2016-03-01 Catholic University Industry Academic Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
WO2015098113A1 (ja) 2013-12-27 2015-07-02 独立行政法人医薬基盤研究所 悪性腫瘍の治療薬
JP6940950B2 (ja) 2014-02-10 2021-09-29 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 細胞遊走を調節するためのＭｃｏｌｎ−１モジュレータの使用
MX373460B (es) 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
JP6771387B2 (ja) 2014-03-25 2020-10-21 アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー
US9856475B2 (en) 2014-03-25 2018-01-02 Arcturus Therapeutics, Inc. Formulations for treating amyloidosis
WO2015148580A2 (en) 2014-03-25 2015-10-01 Arcturus Therapeutics, Inc. Una oligomers having reduced off-target effects in gene silencing
SG11201607772WA (en) 2014-03-31 2016-10-28 Debiopharm Int Sa Fgfr fusions
WO2015153339A2 (en) 2014-04-01 2015-10-08 Monsanto Technology Llc Compositions and methods for controlling insect pests
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
KR101633881B1 (ko) 2014-05-08 2016-06-28 고려대학교 산학협력단 도파민 의존성 신경장애 치료를 위한 REV-ERBα 유전자의 용도
KR101633876B1 (ko) 2014-05-08 2016-06-28 고려대학교 산학협력단 정서장애 및 중독질환 치료를 위한 REV-ERBα 유전자의 용도
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
EP3736334A1 (en) 2014-07-16 2020-11-11 Arrowhead Pharmaceuticals, Inc. Rnai compositions to treat apoc3-related diseases
CN106604993A (zh) 2014-07-29 2017-04-26 孟山都技术公司 用于控制昆虫害虫的组合物和方法
WO2016026258A1 (en) 2014-08-22 2016-02-25 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
US10125092B2 (en) 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2016044271A2 (en) 2014-09-15 2016-03-24 Children's Medical Center Corporation Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
ES2927649T3 (es) 2014-09-25 2022-11-08 Cold Spring Harbor Laboratory Tratamiento del síndrome de Rett
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
WO2016077624A1 (en) 2014-11-12 2016-05-19 Nmc, Inc. Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
EP3778644A3 (en) 2014-12-23 2021-06-02 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
CN108064288B (zh) 2015-01-22 2021-11-26 孟山都技术公司 用于控制叶甲属的组合物和方法
EP3265107B1 (en) 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
US10781446B2 (en) 2015-03-09 2020-09-22 University Of Kentucky Research Foundation RNA nanoparticle for treatment of gastric cancer
CN111961103B (zh) 2015-03-09 2023-06-16 肯塔基大学研究基金会 用于脑肿瘤治疗的rna纳米颗粒
US11085044B2 (en) 2015-03-09 2021-08-10 University Of Kentucky Research Foundation miRNA for treatment of breast cancer
KR101797569B1 (ko) 2015-03-18 2017-11-22 한국교통대학교산학협력단 금속 나노입자 기반 간 표적성 핵산 전달체 및 이의 제조방법
WO2016161299A1 (en) 2015-04-01 2016-10-06 Arcturus Therapeutics, Inc. Therapeutic una oligomers and uses thereof
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
CN107614685B (zh) 2015-04-17 2021-10-19 肯塔基大学研究基金会 Rna纳米颗粒及其使用方法
WO2016176617A2 (en) 2015-04-29 2016-11-03 New York University Method for treating high-grade gliomas
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN108135923B (zh) 2015-07-06 2021-03-02 菲奥医药公司 靶向超氧化物歧化酶1（sod1）的核酸分子
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017015671A1 (en) 2015-07-23 2017-01-26 Arcturus Therapeutics, Inc. Compositions for treating amyloidosis
JP2018525037A (ja) 2015-08-24 2018-09-06 ハロー−バイオ・アールエヌエーアイ・セラピューティックス、インコーポレイテッド 遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
KR20250145703A (ko) 2015-09-02 2025-10-13 알닐람 파마슈티칼스 인코포레이티드 프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
CA2997947A1 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
WO2017059118A1 (en) 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
WO2017070151A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
KR102162324B1 (ko) 2015-10-30 2020-10-07 제넨테크, 인크. 항-HtrA1 항체 및 이의 사용 방법
JP6457704B2 (ja) 2015-12-13 2019-01-23 日東電工株式会社 高活性及びオフターゲット削減のためのｓｉＲＮＡ構造
US11072777B2 (en) 2016-03-04 2021-07-27 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
WO2017173297A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Beta-catenin nucleic acids and uses thereof
WO2017173304A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Kras nucleic acids and uses thereof
FI3445773T3 (fi) 2016-05-13 2023-03-30 4D Molecular Therapeutics Inc Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä
US20190367930A1 (en) 2016-07-29 2019-12-05 Danmarks Tekniske Universitet Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
EP3516062A1 (en) 2016-09-21 2019-07-31 Alnylam Pharmaceuticals, Inc. Myostatin irna compositions and methods of use thereof
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
US11147249B2 (en) 2016-12-08 2021-10-19 Alector Llc Siglec transgenic mice and methods of use thereof
WO2018109222A1 (en) 2016-12-16 2018-06-21 Universite de Bordeaux Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2018232230A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
JP2020523027A (ja) 2017-06-16 2020-08-06 イーエムベーアー−インスティテュート フュール モレクラレ バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 血管オルガノイド、オルガノイドの製造及び使用方法
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
CN117866959A (zh) 2017-09-07 2024-04-12 北京泰德制药股份有限公司 靶向ckip-1的双链rna分子及其用途
US10597657B2 (en) 2017-09-11 2020-03-24 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
IL273245B2 (en) 2017-09-15 2025-03-01 Commw Scient Ind Res Org RNA molecules
SG11202002276VA (en) 2017-09-20 2020-04-29 4D Molecular Therapeutics Inc Adeno-associated virus variant capsids and methods of use thereof
DK3717636T5 (da) 2017-11-27 2024-08-26 4D Molecular Therapeutics Inc Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese
JP7506601B2 (ja) 2017-12-06 2024-06-26 アビディティー バイオサイエンシーズ，インク． 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
CA3086485A1 (en) 2017-12-21 2019-06-27 Alnylam Pharmaceuticals, Inc. Chirally-enriched double-stranded rna agents
US20210162007A1 (en) 2018-04-09 2021-06-03 President And Fellows Of Harvard College Modulating nuclear receptors and methods of using same
EP3801025A4 (en) 2018-05-24 2022-03-09 Sirnaomics, Inc. Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
JP7535495B2 (ja) 2018-07-27 2024-08-16 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－５抗体及びその使用方法
MX2021002299A (es) 2018-08-31 2021-04-28 Alector Llc Anticuerpos de anti-cd33 y metodos para usarlos.
US20210393740A1 (en) 2018-09-19 2021-12-23 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
EP4365289A3 (en) 2018-11-16 2024-07-10 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
KR20220030203A (ko) 2018-12-27 2022-03-10 서나오믹스, 인크. 암 치료를 위한 면역 체크포인트 억제제와 조합하여 전달된 siRNA를 사용하는 TGF-베타1 및 COX2의 사일런싱
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
IT201900005918A1 (it) 2019-04-16 2020-10-16 Pastificio Rana Spa Macchina per cuocere una dose di pasta in un contenitore
US20220290156A1 (en) 2019-08-27 2022-09-15 Sanofi Compositions and methods for inhibiting pcsk9
KR102100163B1 (ko) 2019-09-24 2020-04-13 테고사이언스 (주) 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
JP7682181B2 (ja) 2019-12-18 2025-05-23 ノバルティス アーゲー ３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CN115176005A (zh) 2019-12-18 2022-10-11 诺华股份有限公司 用于治疗血红蛋白病的组合物和方法
WO2021142191A1 (en) 2020-01-08 2021-07-15 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
US12178902B1 (en) 2020-01-12 2024-12-31 University Of Southern California Methods and compositions for fluid drainage by Piezo ion channel activation
US20210222128A1 (en) 2020-01-22 2021-07-22 Massachusetts Institute Of Technology Inducible tissue constructs and uses thereof
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
MX2022013462A (es) 2020-04-27 2022-11-16 4D Molecular Therapeutics Inc Variantes, formulaciones y metodos adeno-asociados para suministro pulmonar.
JP2023546175A (ja) 2020-10-14 2023-11-01 ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド 脂質ナノ粒子製造の方法及びそれに由来する組成物
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
MX2023014041A (es) 2021-05-28 2023-12-15 Shanghai Regenelead Therapies Co Ltd Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion.
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2023012165A1 (en) 2021-08-02 2023-02-09 Universite De Montpellier Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
KR20250068649A (ko) 2022-09-13 2025-05-16 아스널 바이오사이언시스, 인크. 공동 발현된 tgfbr shrna를 갖는 면역 세포
EP4587570A2 (en) 2022-09-16 2025-07-23 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
WO2025157611A1 (en) 2024-01-24 2025-07-31 Basf Se Mixtures comprising rna and fungicides to control phytopathogenic fungi
WO2025157612A1 (en) 2024-01-24 2025-07-31 Basf Se Mixtures comprising rna to control phytopathogenic fungi.
WO2025157614A1 (en) 2024-01-24 2025-07-31 Basf Se Mixtures comprising rna and fungicides to control phytopathogenic fungi
WO2025199338A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Systems targeting slc34a2 and tmprss4 and methods of use thereof

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US5107065A (en) 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5712257A (en) 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
WO1989005345A1 (en) 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5100087A (en) * 1989-03-06 1992-03-31 Ashby Stephen B Fastening device for container liners
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
US5866701A (en) 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
DE69033975T2 (de) 1989-01-23 2002-10-02 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanttherapien für Infektionen und hyperproliferative Störungen
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5112734A (en) 1989-05-26 1992-05-12 Gene-Trak Systems Target-dependent synthesis of an artificial gene for the synthesis of a replicatable rna
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US6245560B1 (en) 1990-01-18 2001-06-12 The United States Of America As Represented By The Department Of Health And Human Services Vector with multiple target response elements affecting gene expression
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5246921A (en) 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
WO1992001806A1 (en) 1990-07-16 1992-02-06 The Public Health Research Institute Of The City Of New York, Inc. Selection of ribozymes that efficiently cleave target rna
JP3249516B2 (ja) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション 遺伝子治療のためのレトロウイルスのベクター
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
US5238470A (en) * 1992-02-21 1993-08-24 Westavco Corporation Emission control device
WO1993018052A1 (en) 1992-03-05 1993-09-16 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
EP1310555A3 (en) 1992-03-16 2003-08-27 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase c
US5496698A (en) 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
US5525468A (en) 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
NZ255028A (en) 1992-07-02 1997-03-24 Hybridon Inc Antisense oligonucleotides resistant to nucleolytic degradation
US6423489B1 (en) 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
NZ257484A (en) 1992-11-03 1997-08-22 Gene Shears Pty Ltd Nucleotides active against tnf-alpha, treatment of viral diseases
US5864028A (en) 1992-11-03 1999-01-26 Gene Shears Pty. Limited Degradation resistant mRNA derivatives linked to TNF-α ribozymes
WO1994013793A1 (en) 1992-12-04 1994-06-23 Apollon, Inc. Compounds and methods for the treatment of leukemias
US5811300A (en) 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5639655A (en) 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
CN1127527A (zh) 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
US5635385A (en) 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
US5755269A (en) * 1993-12-09 1998-05-26 Ciba Corning Diagnostics Corp. Fluid delivery system
US6054299A (en) 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US6143878A (en) 1994-11-29 2000-11-07 The University Of Queensland Sox-9 gene and protein and use in the regeneration of bone or cartilage
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5683873A (en) 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5674683A (en) 1995-03-21 1997-10-07 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides and method of using
US5739271A (en) 1995-06-07 1998-04-14 Gen-Probe Incorporated Thiocationic lipids
JPH11510050A (ja) * 1995-07-25 1999-09-07 イントロヘーネ ベスローテン フェンノートシャップ 標的遺伝子送達のための方法および手段
US6482803B1 (en) 1995-09-01 2002-11-19 Board Of Regents, The University Of Texas System Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
DE69637256T2 (de) * 1996-01-16 2008-06-19 Sirna Therapeutics, Inc., Boulder Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5891717A (en) 1996-01-19 1999-04-06 Betagene, Inc. Methods and compositions for inhibiting hexokinase
US5854067A (en) 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
US6099823A (en) 1996-02-16 2000-08-08 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5731181A (en) 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
DE19618797C2 (de) 1996-05-10 2000-03-23 Bertling Wolf Vehikel zum Transport molekularer Substanz
US6077705A (en) 1996-05-17 2000-06-20 Thomas Jefferson University Ribozyme-mediated gene replacement
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5939262A (en) 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
DE19631919C2 (de) * 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-Sinn-RNA mit Sekundärstruktur
US6255071B1 (en) 1996-09-20 2001-07-03 Cold Spring Harbor Laboratory Mammalian viral vectors and their uses
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
US5968737A (en) 1996-11-12 1999-10-19 The University Of Mississippi Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
US6057156A (en) 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
US6100444A (en) 1997-02-11 2000-08-08 University Of Rochester Medical Center Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6225291B1 (en) 1997-04-21 2001-05-01 University Of Florida Rod opsin mRNA-specific ribozyme compositions and methods for the treatment of retinal diseases
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US6183959B1 (en) 1997-07-03 2001-02-06 Ribozyme Pharmaceuticals, Inc. Method for target site selection and discovery
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
GB9720148D0 (en) 1997-09-22 1997-11-26 Innes John Centre Innov Ltd Gene silencing materials and methods
US6245748B1 (en) 1997-09-26 2001-06-12 Georgetown University Inhibition of an FGF-binding protein using ribozymes
US6355415B1 (en) 1997-09-29 2002-03-12 Ohio University Compositions and methods for the use of ribozymes to determine gene function
US6087164A (en) 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US6087172A (en) 1997-10-31 2000-07-11 Hisamitsu Pharmaceutical Co., Inc. Ribozymes targeted to human IL-15 mRNA
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6100087A (en) 1998-03-11 2000-08-08 City Of Hope Ribozymes targeted to human CCR5 mRNA
WO1999049029A1 (en) * 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
NZ507093A (en) * 1998-04-08 2003-08-29 Commw Scient Ind Res Org Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
AU3751299A (en) 1998-04-20 1999-11-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6010907A (en) 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
AR020078A1 (es) * 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
MXPA01003642A (es) 1998-10-09 2003-07-21 Ingene Inc Sintesis enzimatica de adnss.
BR9914773A (pt) 1998-10-09 2002-02-05 Ingene Inc Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6200924B1 (en) 1999-01-29 2001-03-13 E. I. Du Pont De Nemours And Company Porous highly fluorinated acidic polymer catalyst
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000063364A2 (en) * 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
HUP0201235A3 (en) 1999-05-10 2004-10-28 Syngenta Participations Ag Regulation of viral gene expression
US6861220B2 (en) 1999-09-08 2005-03-01 Ramot University Authority For Applied Research & Industrial Development Ltd Genetic screening methods
US6569623B1 (en) 1999-09-08 2003-05-27 Ramot University Authority For Applied Research & Industrial Development Ltd. Genetic screening methods
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
RU2164944C1 (ru) 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
GB9930691D0 (en) 1999-12-24 2000-02-16 Devgen Nv Improvements relating to double-stranded RNA inhibition
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
MXPA02009069A (es) 2000-03-17 2004-04-05 Benitec Australia Ltd Silenciamiento genetico.
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
ATE513910T1 (de) 2000-05-30 2011-07-15 Johnson & Johnson Res Pty Ltd Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren
AU2001284160A1 (en) 2000-08-19 2002-03-04 Axordia Limited Modulation of stem cell differentiation
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
AU2001296333A1 (en) 2000-09-26 2002-04-08 The Burnham Institute Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
WO2002061034A2 (en) 2000-12-08 2002-08-08 Invitrogen Corporation Compositions and methods for rapidly generating recombinant nucleic acid molecules
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
DE10100588A1 (de) 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US6335415B1 (en) * 2001-01-30 2002-01-01 Council Of Scientific & Industrial Research Process for the preparation of a polyester
AU2002256990A1 (en) 2001-02-07 2002-09-24 The Burnham Institute Apoptosis modulator bcl-b and methods for making and using same
GB0104948D0 (en) 2001-02-28 2001-04-18 Novartis Res Foundation Novel methods
AU2002258477A1 (en) 2001-03-08 2002-09-24 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
US6787063B2 (en) 2001-03-12 2004-09-07 Seiko Epson Corporation Compositions, methods for producing films, functional elements, methods for producing functional elements, methods for producing electro-optical devices and methods for producing electronic apparatus
WO2003070969A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2345720A3 (en) 2001-07-12 2012-01-25 University of Massachusetts In vivo production of small interfering RNAs that mediate gene silencing
GB0118223D0 (en) 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
AU2002329667A1 (en) 2001-07-30 2003-02-17 Uta Griesenbach Specific inhibition of gene expression by small double stranded rnas
WO2003016572A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Oligonucleotide therapeutics for treating hepatitis c virus infections
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
WO2003035083A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
DE10230996A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Behandlung eines Pankreaskarzinoms
WO2003035870A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur behandlung eines pankreaskarzinoms
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
CN1608133A (zh) 2001-10-26 2005-04-20 里伯药品公司 双链核糖核酸用于治疗正(+)链rna病毒感染的用途
EP1575976A4 (en) 2001-11-02 2006-08-23 Insert Therapeutics Inc METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
WO2003044161A2 (en) 2001-11-15 2003-05-30 Tularik Inc. Gene amplification and overexpression in cancer
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
GB2397062B (en) 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
EP1476459A4 (en) 2002-02-20 2005-05-25 Sirna Therapeutics Inc INHIBITION OF RNA INTERFERENCE-INDUCED CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2003070283A2 (en) 2002-02-22 2003-08-28 Klaus Strebhardt Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
US20030180756A1 (en) 2002-03-21 2003-09-25 Yang Shi Compositions and methods for suppressing eukaryotic gene expression
DE10230966A1 (de) 2002-07-10 2004-01-22 Ina-Schaeffler Kg Elektromagnetisches Hydraulikventil, insbesondere Proportionalventil zur Steuerung einer Vorrichtung zur Drehwinkelverstellung einer Nockenwelle gegenüber einer Kurbelwelle einer Brennkraftmaschine
AU2003260370B2 (en) 2002-08-05 2008-05-22 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
AU2003273336A1 (en) 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
DE10302421A1 (de) 2003-01-21 2004-07-29 Ribopharma Ag Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
GB0317988D0 (en) 2003-07-31 2003-09-03 Milner Jo Splicing variants
NZ556097A (en) 2005-01-07 2009-12-24 Alnylam Pharmaceuticals Inc Rnai modulation of RSV and therapeutic uses thereof
US7718629B2 (en) 2006-03-31 2010-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 gene

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329463B2 (en) 2000-12-01 2012-12-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US8524681B2 (en) 2007-09-19 2013-09-03 Applied Biosystems, Llc siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof
US9273312B2 (en) 2007-09-19 2016-03-01 Applied Biosystems, Llc SiRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof
US9284551B2 (en) 2007-09-19 2016-03-15 Applied Biosystems, Llc RNAi sequence-independent modification formats, and stabilized forms thereof
CN101525388B (zh) * 2009-02-20 2012-02-01 中国人民解放军第四军医大学 特异性双链rna结合蛋白嵌合体及其在病毒感染性疾病中的应用

Also Published As

Publication number Publication date
US20050100907A1 (en) 2005-05-12
DE50000414D1 (de) 2002-10-02
US8114851B2 (en) 2012-02-14
JP2009100757A (ja) 2009-05-14
EP2363479A1 (de) 2011-09-07
EP3018207A1 (de) 2016-05-11
JP2013074901A (ja) 2013-04-25
EP1798285A1 (de) 2007-06-20
JP2010057515A (ja) 2010-03-18
US20040072779A1 (en) 2004-04-15
JP2010057514A (ja) 2010-03-18
JP2009102380A (ja) 2009-05-14
US20130164843A1 (en) 2013-06-27
EP1214945B1 (de) 2005-06-08
JP2007031443A (ja) 2007-02-08
CY1119221T1 (el) 2018-02-14
US8101742B2 (en) 2012-01-24
JP2009100758A (ja) 2009-05-14
DK1214945T4 (da) 2018-11-05
DE10080167B4 (de) 2008-03-20
PT1214945E (pt) 2005-10-31
PT1798285T (pt) 2017-06-26
JP2003502012A (ja) 2003-01-21
US20140220113A1 (en) 2014-08-07
DE10066235B4 (de) 2008-04-10
DE10066235C5 (de) 2014-08-21
JP2006340732A (ja) 2006-12-21
US20080261303A1 (en) 2008-10-23
EP1214945A2 (de) 2002-06-19
US20080171862A1 (en) 2008-07-17
EP1144623B9 (de) 2003-03-05
ATE222953T1 (de) 2002-09-15
US9133454B2 (en) 2015-09-15
AU778474B2 (en) 2004-12-09
EP1550719B1 (de) 2008-12-24
ATE297463T1 (de) 2005-06-15
PT2363479T (pt) 2016-10-18
US20080233651A1 (en) 2008-09-25
WO2000044895A1 (de) 2000-08-03
JP2008005844A (ja) 2008-01-17
AU3271300A (en) 2000-08-18
DE20023125U1 (de) 2003-05-15
ES2628535T3 (es) 2017-08-03
US20130164366A1 (en) 2013-06-27
EP1214945B2 (de) 2018-10-10
DE50010528D1 (de) 2005-07-14
EP1144623A1 (de) 2001-10-17
ES2597953T3 (es) 2017-01-24
HK1160487A1 (zh) 2012-08-17
JP6471901B2 (ja) 2019-02-20
US8729037B2 (en) 2014-05-20
US8114981B2 (en) 2012-02-14
EP1798285B1 (de) 2017-03-15
US9902954B2 (en) 2018-02-27
US20040053875A1 (en) 2004-03-18
US20040102408A1 (en) 2004-05-27
US9902955B2 (en) 2018-02-27
JP2007312784A (ja) 2007-12-06
DK2363479T3 (en) 2016-10-31
PT1550719E (pt) 2009-03-13
US8202980B2 (en) 2012-06-19
US20080171861A1 (en) 2008-07-17
US20140051166A1 (en) 2014-02-20
DE50015501D1 (de) 2009-02-05
US8183362B2 (en) 2012-05-22
JP2007314555A (ja) 2007-12-06
DE20023125U8 (de) 2005-01-20
DK1550719T3 (da) 2009-04-27
EP1214945A3 (de) 2002-09-04
ES2321409T3 (es) 2009-06-05
EP1550719A1 (de) 2005-07-06
JP2015146823A (ja) 2015-08-20
ES2182791T3 (es) 2003-03-16
DE10080167D2 (de) 2002-02-28
EP1144623B1 (de) 2002-08-28
US8119608B2 (en) 2012-02-21
ES2243608T5 (es) 2019-03-21
CY1108896T1 (el) 2014-07-02
EP2363479B1 (de) 2016-07-13
JP5990468B2 (ja) 2016-09-14
US20080166800A1 (en) 2008-07-10
JP2019017390A (ja) 2019-02-07
US20130177631A1 (en) 2013-07-11
US8168776B2 (en) 2012-05-01
US20140220676A1 (en) 2014-08-07
DE19956568A1 (de) 2000-08-17
ATE418610T1 (de) 2009-01-15
ZA200105909B (en) 2002-07-24
AU2005201044A1 (en) 2005-04-07
CY1118264T1 (el) 2017-06-28
US20080182981A1 (en) 2008-07-31
DK1798285T3 (en) 2017-07-03
US8101584B2 (en) 2012-01-24
AU2005201044B2 (en) 2008-05-29
US20180179526A1 (en) 2018-06-28
CA2359180A1 (en) 2000-08-03
DK1214945T3 (da) 2005-09-26
US8877726B2 (en) 2014-11-04
ES2243608T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
CA2359180C (en) Method and medicament for inhibiting the expression of a given gene
AU2008202208B2 (en) Method and medicament for inhibiting the expression of a defined gene
AU2017276342A1 (en) Method and medicament for inhibiting the expression of a defined gene

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200129